JAZZ$203.42
$203.12
Chart
Performance
Key Stats
AI JAZZ Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyJazz Pharmaceuticals shows solid fundamental performance and positive thematic alignment in the healthcare sector, with some technical indicators suggesting potential near-term caution. It is well-positioned for long-term investors.
Thematic
Jazz Pharmaceuticals operates within the biopharmaceutical sector, benefiting from trends in specialty therapeutics, sleep disorders, and oncology. Growth in these areas presents a positive outlook.
Fundamental
Jazz Pharmaceuticals demonstrates robust revenue growth and improving profitability, supported by a solid balance sheet and strong cash flow generation. While valuation metrics are somewhat elevated, the company's financial health is a significant positive.
Technical
The stock is trading above key moving averages, indicating a generally positive trend. However, some momentum oscillators are entering overbought territory, suggesting a potential for a short-term pause or pullback.
| Factor | Score |
|---|---|
| Specialty Pharmaceuticals Growth | 80 |
| Drug Pipeline & Innovation | 75 |
| Aging Global Population | 65 |
| Regulatory Landscape | 60 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 85 |
| Growth | 75 |
| Balance Sheet Health | 60 |
| Cash Flow | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 55 |
| Volume Confirmation | 60 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Earnings Surprise Trend
The company has exceeded earnings per share (EPS) estimates in 7 of the last 8 quarters, indicating consistent operational efficiency and better-than-expected profitability.
Undervalued Relative to Earnings
The Price-to-Earnings (P/E) TTM ratio of 16.03 is lower than the industry average of 20.5, suggesting the stock may be undervalued based on its current earnings.
Bearish Points (7)
Recent Earnings Miss
The company missed its EPS estimate in Q2 2025 by 63.93% ($1.68 reported vs. $4.66 estimated), signaling potential operational challenges or unexpected expenses.
High Price-to-Sales Ratio
The Price-to-Sales (PS) ratio for 2025 is 8.4 (Q1), which is significantly higher than the trailing twelve months (TTM) PS of 2.3, suggesting potential overvaluation if future revenue growth falters.
Calendar
August 2025
6
Next Earnings Date
H: $4.47
A: $-6.25
L: $-9.61
H: 1.08B
A: 1.05B
L: 988.65M
Profile
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Seasonals
Price Target
185.68 USD
The 39 analysts offering 1 year price forecasts for JAZZ have a max estimate of 230.00 and a min estimate of 147.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in the narcolepsy market with its drug WAKIX, similar to Jazz's Xyrem/Xywav, addressing the same patient population.
Weight: 95
Direct competitor in the narcolepsy market with its newly approved once-nightly drug Lumryz, posing a direct challenge to Jazz's dominant position.
Weight: 90
Focuses on CNS disorders, including depression and narcolepsy, with products like Sunosi which Jazz previously sold to Axsome, maintaining therapeutic area overlap.
Weight: 85
Specialty biopharmaceutical company with a strong pipeline and marketed products in hematology and oncology, aligning closely with Jazz's oncology segment.